<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01713335</url>
  </required_header>
  <id_info>
    <org_study_id>C11-56</org_study_id>
    <secondary_id>2012-A00885-38</secondary_id>
    <nct_id>NCT01713335</nct_id>
  </id_info>
  <brief_title>Proteasis Evaluation in COPD</brief_title>
  <acronym>Pro-BPCO</acronym>
  <official_title>Proteasis Evaluation in COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to evaluate kallikreins and its substrate, CCN, in COPD patients.
      Kallikreins are a subgroup of serine proteases, enzymes which are able to cleave peptide
      bonds in proteins. Kallicrein profile is unkonwn in COPD. The investigators will assess
      Kallikrein 1 to 15 and CCN 1 to 6 in sputum of patients. Three groups of patients will be
      included: Healthy smoker subjects, stable COPD patients and COPD patients with acute
      exacerbation. Kallicrein levels in sputum will be compared in these groups.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Kallikrein level in sputum by ELISA</measure>
    <time_frame>One sample at inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison between kallikrein level and clinical or functionnal parameters</measure>
    <time_frame>All data will be identified at inclusion</time_frame>
    <description>Correlation between kallikrein and FEV1 Correlation between kallikrein and dyspnea score</description>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Sputum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Stable COPD patients were recruited from pulmonary primary care of pulmonary division of
        CHRU of Tours.

        COPD with acute exacerbation were recruited from hospitalisation of pulmonary division of
        CHRU of Tours and intensive care unit of CHRU of Tours.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for healthy subjects:

          -  Smoker with tobacco consumption of 20 pack/year

          -  Normal lung function tests

        Exclusion Criteria for healthy subjects:

          -  diagnosis of lung disease during the study

          -  Asthma

          -  Lung cancer

          -  Pregnant and lactating women

        Inclusion Criteria for stable COPD:

          -  Smoker with tobacco consumption of 20 pack/year

          -  FEV1/FVC&lt;70% on lung function tests

          -  no hospitalisation for exacerbation during 3 months before inclusion

        Exclusion Criteria for stable COPD:

          -  Asthma

          -  Lung cancer

          -  Pregnant and lactating women

        Inclusion Criteria for COPD with exacerbation:

          -  Smoker with tobacco consumption of 20 pack/year

          -  worsening of pulmonary symptoms

          -  FEV1/FVC&lt;70% on lung function tests could be obtain before or 3 months after
             exacerbation

        Exclusion Criteria for COPD with exacerbation:

          -  Asthma

          -  Lung cancer

          -  Pregnant and lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent Guilleminault, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Pneumologie, CHRU Tours, Tours, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Valérie Gissot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre d'Investigation Clinique, CHRU Tours, Tours, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antoine Guillon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Réanimation médicale, CHRU Tours, Tours, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurent Guilleminault, MD</last_name>
    <email>guillel@free.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Guilleminault, MD</last_name>
      <email>guillel@free.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent Guilleminault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2012</study_first_submitted>
  <study_first_submitted_qc>October 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2012</study_first_posted>
  <last_update_submitted>April 24, 2015</last_update_submitted>
  <last_update_submitted_qc>April 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

